Cell Therapeutics’ Adaptive Trials For Lymphoma Treatment Pixantrone Could Meet Endpoints Early
This article was originally published in The Pink Sheet Daily
Executive Summary
Meeting endpoints early would allow NDA filing in second half of 2008, CEO James Bianco tells “The Pink Sheet” DAILY.
You may also be interested in...
CTI Launches Phase III Trial Of Pixantrone In Indolent NHL
Pixantrone provides improvement over standard care for patients with relapsed follicular disease, CEO Bianco tells “The Pink Sheet” DAILY.
CTI Launches Phase III Trial Of Pixantrone In Indolent NHL
Pixantrone provides improvement over standard care for patients with relapsed follicular disease, CEO Bianco tells “The Pink Sheet” DAILY.
CTI Anticipates Preliminary Data From Pivotal Pixantrone Trial In Mid-2008
Firm is forging ahead with non-Hodgkin’s lymphoma program following positive special protocol assessment from FDA.